R&D channel feed – Endpoints News

R&D channel feed

#JPM20: 'The NPV is always wrong.' Takeda preps another spinout — this time on psych

6 years ago

‘Clinical superiority’: diazepam nasal spray illustrates FDA parameters for orphan drug exclusivity

6 years ago

Another opioid pain drug, really? FDA staff sound sour on Nektar analgesic

6 years ago

Amarin's Vascepa reigns supreme in fish oil battle, as AstraZeneca's rival fizzles

6 years ago

That company suing Patrick Soon-Shiong for $1B? Someone's trying to buy it for $1B

6 years ago

Targeting the BFPs of the CNS, Biogen licenses map of genetic neighborhoods in the brain

6 years ago

Moderna CEO Bancel offers a thumbs-up on latest update for their CMV program — with blockbuster hopes for what's ahead

6 years ago

Second pivotal study bodes well for VBI's hep B vaccine

6 years ago

Controversial Duchenne MD player Solid Bio takes another hit, laying off staffers in a bid to weather FDA hold

6 years ago

Regeneron’s pivotal trial for an ultra-rare disease fails the primary — but don't count them out at the FDA

6 years ago

Sanofi antes up $55M to add protein degradation tech to the R&D playbook as execs look to revive the pipeline

6 years ago

ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results

6 years ago

Scoop: Sanofi quietly ties up with a low-profile, preclinical cancer biotech — FTC signs off

6 years ago

Stanley and Rosanne Crooke stay focused on anti-sense, stealing back patients from disease with N-of-1 tech

6 years ago

Steepest decline in US cancer mortality ever recorded, study finds

6 years ago

Mark Alles begins his post-Celgene career on the board of a US-China biotech led by a former colleague

6 years ago

How pancreatic RAS tumors protect themselves. Researchers point to a new protein — and maybe a new treatment

6 years ago

Thomas Lynch finds a new home as leader of the Fred Hutch — and he’s staying focused on cancer breakthroughs

6 years ago

Apellis soars as Alexion rival outshines blockbuster standard bearer Soliris — then fresh doubts scuttle spike

6 years ago

A Bay Area biotech spells out the stock package it used to woo a new CEO from Big Pharma

6 years ago

Merck's PD-1 star Keytruda flunks a key survival endpoint in SCLC — cue the unfavorable Tecentriq comparisons

6 years ago

UCSD scientists' mouse study spotlights possible path to an ALS gene therapy

6 years ago

Chinese investors spearhead a $90M raise for respiratory biotech's pipeline building

6 years ago

Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores

6 years ago

First page Previous page 215 216 217218219 220 221 Next page Last page